Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand

Chang, AB, Bell, SC, Byrnes, CA, Grimwood, K, Holmes, PW, King, PT, Kolbe, J, Landau, LI, Maguire, GP, McDonald, MI, Reid, DW, Thien, FC and Torzillo, PJ (2010) Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Medical Journal of Australia, 193 6: 356-365.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ_218965_Combined.pdf HERDC Combined - not publicly available application/pdf 765.90KB 11
Author Chang, AB
Bell, SC
Byrnes, CA
Grimwood, K
Holmes, PW
King, PT
Kolbe, J
Landau, LI
Maguire, GP
McDonald, MI
Reid, DW
Thien, FC
Torzillo, PJ
Title Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand
Journal name Medical Journal of Australia   Check publisher's open access policy
ISSN 0025-729X
Publication date 2010-09
Sub-type Article (original research)
Volume 193
Issue 6
Start page 356
End page 365
Total pages 10
Place of publication Strawberry Hills, NSW, Australia
Publisher Australasian Medical Publishing
Collection year 2011
Language eng
Subject 11 Medical and Health Sciences
Abstract Consensus recommendations for managing chronic suppurative lung disease (CSLD) and bronchiectasis, based on systematic reviews, were developed for Australian and New Zealand children and adults during a multidisciplinary workshop. • The diagnosis of bronchiectasis requires a high-resolution computed tomography scan of the chest. People with symptoms of bronchiectasis, but non-diagnostic scans, have CSLD, which may progress to radiological bronchiectasis. • CSLD/bronchiectasis is suspected when chronic wet cough persists beyond 8 weeks. Initial assessment requires specialist expertise. Specialist referral is also required for children who have either two or more episodes of chronic (>4 weeks) wet cough per year that respond to antibiotics, or chest radiographic abnormalities persisting for at least 6 weeks after appropriate therapy. • Intensive treatment seeks to improve symptom control, reduce frequency of acute pulmonary exacerbations, preserve lung function, and maintain a good quality of life. • Antibiotic selection for acute infective episodes is based on results of lower airway culture, local antibiotic susceptibility patterns, clinical severity and patient tolerance. Patients whose condition does not respond promptly or adequately to oral antibiotics are hospitalised for more intensive treatments, including intravenous antibiotics. • Ongoing treatment requires regular and coordinated primary health care and specialist review, including monitoring for complications and comorbidities. • Chest physiotherapy and regular exercise should be encouraged, nutrition optimised, environmental pollutants (including tobacco smoke) avoided, and vaccines administered according to national immunisation schedules. • Individualised long-term use of oral or nebulised antibiotics, corticosteroids, bronchodilators and mucoactive agents may provide a benefit, but are not recommended routinely. © Copyright 2010 Elsevier B.V., All rights reserved.
Keyword Cystic fibrosis bronchiectasis
High- Resolution CT
Non-CF Bronchiectasis
Idiopathic Bronchiectasis
Physical Therapy
Health status
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 49 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 24 Oct 2010, 00:05:50 EST